(Q46731906)

English

Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18302712

Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16. (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18302712

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

Charles-Antoine Dutertre

2

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18302712

Hélène Merle-Béral

16

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18302712

Magali Le Garff-Tavernier

object named as

Magali Le Garff-Tavernier

3

0 references

author name string

Christophe de Romeuf

1

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18302712

Nathalie Fournier

4

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18302712

Christine Gaucher

5

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18302712

Arnaud Glacet

6

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18302712

Sylvie Jorieux

7

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18302712

Nicolas Bihoreau

8

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18302712

Christian K Behrens

9

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18302712

Roland Béliard

10

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18302712

Vincent Vieillard

11

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18302712

Bruno Cazin

12

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18302712

Dominique Bourel

13

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18302712

Jean-François Prost

14

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18302712

Jean-Luc Teillaud

15

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18302712

language of work or name

0 references

publication date

1 March 2008

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18302712

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18302712

140

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18302712

6

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18302712

635-643

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18302712

Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06974.X

21 January 2018

Profiling glycoprotein n-linked oligosaccharide by capillary electrophoresis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06974.X

21 January 2018

Monoclonal antibody therapy for B-cell malignancies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06974.X

21 January 2018

Monoclonal antibody as therapy for malignant lymphomas

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06974.X

21 January 2018

Rituximab therapy in malignant lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06974.X

21 January 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06974.X

21 January 2018

Rapid single-step FCGR3A genotyping based on SYBR Green I fluorescence in real-time multiplex allele-specific PCR.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06974.X

21 January 2018

Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06974.X

21 January 2018

Complement activation determines the therapeutic activity of rituximab in vivo.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06974.X

21 January 2018

Isolation and characterization of the B-cell marker CD20.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06974.X

21 January 2018

FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06974.X

21 January 2018

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06974.X

21 January 2018

The mechanisms of action of rituximab in the elimination of tumor cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06974.X

21 January 2018

Emerging information on the use of rituximab in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06974.X

21 January 2018

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06974.X

21 January 2018

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06974.X

21 January 2018

Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06974.X

21 January 2018

Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06974.X

21 January 2018

Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06974.X

21 January 2018

Calcein-acetyoxymethyl cytotoxicity assay: standardization of a method allowing additional analyses on recovered effector cells and supernatants

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06974.X

21 January 2018

Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06974.X

21 January 2018

Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06974.X

21 January 2018

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06974.X

21 January 2018

The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06974.X

21 January 2018

Selection of a human anti-RhD monoclonal antibody for therapeutic use: impact of IgG glycosylation on activating and inhibitory Fc gamma R functions

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06974.X

21 January 2018

Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06974.X

21 January 2018

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06974.X

21 January 2018

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06974.X

21 January 2018

Signaling function of reconstituted CD16: zeta: gamma receptor complex isoforms

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06974.X

21 January 2018

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06974.X

21 January 2018

Identifiers

10.1111/J.1365-2141.2007.06974.X

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18302712

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 December 2017

http://europepmc.org/abstract/MED/18302712

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46731906&oldid=1474740700"